194 related articles for article (PubMed ID: 29385679)
1. The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer.
Fan HC; Chi CS; Chang YK; Tung MC; Lin SZ; Harn HJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385679
[TBL] [Abstract][Full Text] [Related]
2. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
3. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo.
Tsai NM; Chen YL; Lee CC; Lin PC; Cheng YL; Chang WL; Lin SZ; Harn HJ
J Neurochem; 2006 Nov; 99(4):1251-62. PubMed ID: 16987298
[TBL] [Abstract][Full Text] [Related]
4. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
6. Encapsulated
Lin YL; Huang XF; Chang KF; Liao KW; Tsai NM
Int J Nanomedicine; 2020; 15():749-760. PubMed ID: 32099363
[TBL] [Abstract][Full Text] [Related]
7. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
10. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
11. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.
Chowdhury FA; Hossain MK; Mostofa AGM; Akbor MM; Bin Sayeed MS
Biomed Res Int; 2018; 2018():4010629. PubMed ID: 29651429
[TBL] [Abstract][Full Text] [Related]
14. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
15. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
17. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
18. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
[TBL] [Abstract][Full Text] [Related]
19. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
